Integrated Genomics Conference and Seminar Series

Integrating genomic data has proven to be an effective means of achieving focused discovery and faster validation in cancer studies. Affymetrix' integrated solutions provide powerful tools for unlocking the cancer genome, by allowing you to study copy number, allele-specific copy number, loss of heterozygosity, gene expression, exon expression and alternative splicing data using a single sample and only two arrays—the GeneChip® Exon Array and the SNP Array 6.0.

To demonstrate the value of integrated genomics studies, Affymetrix is pleased to announce the first Integrated Genomics Conference and Seminar Series. This series will feature presentations from top scientists that have published using this approach. Space is limited, so please register early to reserve your seat.

Featured Presentations:

Whole-genome Approaches to Identify Genetic Variants Associated with Chemotherapeutic-induced Toxicity

M. Eileen Dolan, Ph.D., Professor of Medicine, Department of Medicine, University of Chicago

Integrated Genomic Profiling of Chronic Lymphocytic Leukemia and Acute Myelogenous Leukemia

Sami Malek, M.D., Assistant Professor, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center

Molecular Characterization of the Pediatric Preclinical Testing Panel

Peter J. Houghton, Ph.D., Chair, Molecular Pharmacology, St. Jude Children's Research Hospital

Advancements and Challenges in Genomic Modeling of Malignant Melanoma

William M. Lin, Computational Biologist, Broad Institute of M.I.T. and Harvard and Yale University, School of Medicine

"Population differences in gene expression have only recently begun to be investigated We believe they play a significant role in susceptibility to disease and in regulating drug response. Our current research focuses on how these genetic and expression differences play a role in sensitivity to adverse effects associated with chemotherapy"
M. Eileen Dolan, Ph.D.

"Using a combination of Affymetrix SNP arrays and expression arrays, we are identifying genes that are differentially expressed between genetic subtypes. Through these efforts we hope to improve our understanding of the role these lesions play in these leukemias potentially identifying novel biomarkers or targets for therapy."
Sami Malek, M.D.

"We identified 493 copy-number altered genes that are non-random and appear to identify histotype-specific programs of genetic alterations. These data indicate that the preclinical models accurately recapitulate expression profiles and genetic alterations common to childhood cancer, supporting their value in drug development."
Peter J. Houghton, Ph.D.

"Overall, the large-scale application of these approaches to genetically annotated cancer cell culture models should... [offer] new therapeutic possibilities in melanoma and many other solid tumors."
William M. Lin

Integrated Genomics Conferences

Integrated Genomics Seminar Series

In addition to the all-day conferences, Affymetrix will host a series of lunchtime seminars at universities throughout the U.S., Canada, Europe and Asia. These presentations are open to the public, but registration is required due to limited seating.

Find a seminar near you >